Alex Rodriguez TRT: What He Said About Medication and What the Science Shows

What Alex Rodriguez Has Said Publicly About Testosterone and PEDs

Rodriguez's public record on testosterone use spans more than a decade and includes at least three distinct moments of disclosure, each with a different level of specificity.

The 2009 Sports Illustrated Admission

In February 2009, Sports Illustrated reporter Selena Roberts confronted Rodriguez with evidence that he had tested positive for two anabolic steroids, testosterone and Primobolan, during the 2003 MLB survey testing period. Rodriguez confirmed the use in a subsequent ESPN interview, stating: "I did take a banned substance. And for that, I am very sorry and deeply regretful." He attributed his use to the "loosey-goosey" atmosphere of the Texas Rangers organization at the time and said he had not used any banned substance since 2003. That statement later came into question.

The 2013 Biogenesis Press Conference

When the Biogenesis investigation became public in August 2013, Rodriguez held a press conference in Chicago and denied current use while simultaneously filing suit against MLB and the players' union. He said he intended to "tell my story" but provided few clinical details. No named physician or specific prescription was identified in his public statements at that time. This portion of his record relies on reported speech rather than a primary transcript, and readers should treat it accordingly.

Post-Retirement Statements and Podcasts

Since retiring in 2016, Rodriguez has appeared on multiple podcasts and media platforms without providing new clinical specifics about any ongoing or past testosterone protocol. He has discussed health optimization broadly, including diet and exercise, but no verified primary source documents a current or supervised TRT prescription. Any claim that he currently takes therapeutic testosterone should be treated as inference until a primary statement surfaces.

The Biogenesis Case: What the MLB Investigation Actually Found

The Biogenesis clinic, operated by Anthony Bosch in Coral Gables, Florida, was investigated by MLB beginning in early 2013. MLB obtained records including client logs, text messages, and handwritten notebooks that Bosch himself later cooperated in authenticating.

Substances Linked to Rodriguez

MLB's investigation, as reported by the New York Times and corroborated by the arbitration record released in part in 2014, identified testosterone cream, human growth hormone, and peptides including IGF-1 precursors as substances Bosch supplied to Rodriguez. Testosterone cream is a transdermal formulation that raises serum testosterone and evades some urine detection windows compared with injectable testosterone cypionate or enanthate. From a pharmacology standpoint, exogenous testosterone at supraphysiologic doses suppresses endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through hypothalamic-pituitary-gonadal axis feedback, a mechanism well-documented in the clinical literature (Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism. J Clin Endocrinol Metab. 2018).

The Arbitration Outcome

An independent arbitrator upheld the 162-game suspension in January 2014 after a lengthy hearing. Rodriguez's legal team argued the evidence was obtained improperly and that Bosch was an unreliable witness. The arbitrator disagreed. Rodriguez served the full suspension, forfeiting approximately $25 million in salary.

Why This Differs from Supervised TRT

Supraphysiologic testosterone dosing for athletic performance is categorically different from physician-prescribed TRT for diagnosed hypogonadism. The Endocrine Society's 2018 clinical practice guideline recommends TRT only when serum total testosterone is consistently below 300 ng/dL on two morning measurements, accompanied by symptoms of deficiency (Bhasin S, et al. J Clin Endocrinol Metab. 2018). Performance doping typically targets testosterone levels two to five times above the normal male reference range of 300 to 1,000 ng/dL.

What Testosterone Actually Does: Clinical Pharmacology

Understanding what Rodriguez allegedly used requires a brief review of testosterone's mechanism, because the word "testosterone" covers a wide pharmacological spectrum depending on dose, formulation, and intent.

Endogenous vs. Exogenous Testosterone

The testes produce roughly 3 to 10 mg of testosterone per day in healthy adult men, regulated by pulsatile LH release from the pituitary. Exogenous testosterone, whether as a cream, injectable ester, or pellet, bypasses this regulatory loop. At therapeutic doses (50 to 100 mg testosterone cypionate per week), the goal is to restore serum levels to the mid-normal range (400 to 700 ng/dL). At supraphysiologic doses (300 to 600 mg per week or more, common in documented doping cases), levels can reach 2,000 to 4,000 ng/dL, producing significant lean-mass accretion and red blood cell increases (Basaria S. Male hypogonadism. Lancet. 2014).

Anabolic Effects Relevant to Athletic Performance

A 2013 meta-analysis of 18 randomized controlled trials published in the Journal of Clinical Endocrinology and Metabolism found that testosterone administration increased lean body mass by a mean of 1.6 kg and reduced fat mass by 1.6 kg across treatment durations of 3 to 12 months (Corona G, et al. J Clin Endocrinol Metab. 2013). These effects scale with dose, which is why sports governing bodies prohibit any exogenous testosterone above the endogenous reference range. The World Anti-Doping Agency (WADA) sets a urinary testosterone-to-epitestosterone (T/E) ratio threshold of 4:1 as a preliminary positive, with isotope-ratio mass spectrometry used to confirm exogenous origin.

Primobolan: The Second Drug Named in 2009

Primobolan (methenolone) is a synthetic anabolic-androgenic steroid with a relatively low androgenic index, making it harder to detect than testosterone on standard immunoassay panels. Its inclusion in the 2003 positive test alongside testosterone suggests a stack designed to maximize anabolic effect while partially avoiding detection, a strategy described in the doping literature (Thevis M, Schanzer W. Mass spectrometry in sports drug testing. Mass Spectrometry Reviews. 2007).

Hypogonadism in Retired Athletes: The Clinical Picture

Some former professional athletes do develop genuine hypogonadism after retirement, partly because years of supraphysiologic testosterone use can suppress the hypothalamic-pituitary-gonadal axis long after cessation.

Post-Cycle Hypogonadism: A Real Clinical Entity

Prolonged exogenous androgen exposure causes testicular atrophy and suppression of gonadotropin secretion. Recovery of the hypothalamic-pituitary-gonadal axis after stopping androgens can take 6 to 24 months and, in some cases, may be permanent. A 2015 study in the Journal of Clinical Endocrinology and Metabolism found that former anabolic-androgenic steroid users had significantly lower LH and testosterone levels than age-matched controls who had never used AAS, with some men meeting laboratory criteria for hypogonadism years after their last cycle (Rasmussen JJ, et al. J Clin Endocrinol Metab. 2016).

Does Rodriguez Have a Diagnosed Medical Need? What the Record Shows

No public primary source, not a physician statement, not a court filing, not a self-disclosure, documents that Rodriguez has been diagnosed with hypogonadism or that he holds a current legal prescription for testosterone replacement. Any assertion to that effect is inference. Clinicians evaluating a retired athlete with a history of androgen use should obtain a full hormone panel including total testosterone, free testosterone, LH, FSH, sex hormone-binding globulin (SHBG), and prolactin before prescribing TRT. The American Urological Association's 2018 guideline on testosterone deficiency specifies that two separate morning testosterone measurements below 300 ng/dL are required before initiating therapy (Mulhall JP, et al. AUA Guideline. J Urology. 2018).

When TRT Is Medically Appropriate

Symptoms that prompt evaluation for hypogonadism include reduced libido, fatigue, loss of muscle mass, depressed mood, and erectile dysfunction. The FDA has approved testosterone products specifically for men with primary or secondary hypogonadism confirmed by laboratory testing (FDA. Approved Risk Evaluation and Mitigation Strategy: Testosterone Products. 2015). Off-label use for age-related low-normal testosterone without symptoms is not guideline-endorsed and carries cardiovascular risk that requires monitoring.

Cardiovascular and Other Risks of Testosterone: What the Evidence Shows

Whether the context is therapeutic TRT or prior supraphysiologic doping, testosterone carries cardiovascular implications that any patient, including a retired athlete, must understand.

The TRAVERSE Trial

The most rigorous recent evidence on cardiovascular safety of TRT is the TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023. Men aged 45 to 80 with hypogonadism and existing cardiovascular disease or high cardiovascular risk were randomized to testosterone gel or placebo for a mean of 22 months. The primary cardiovascular endpoint was non-inferior between groups (hazard ratio 0.96, 95% CI 0.78 to 1.17), but the testosterone arm showed a higher incidence of atrial fibrillation (3.5% vs. 2.4%), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury (Lincoff AM, et al. NEJM. 2023). These findings do not eliminate TRT as an option but do require individualized risk assessment.

Hematocrit Elevation

Testosterone stimulates erythropoietin production, raising hematocrit. Clinical guidelines recommend monitoring hematocrit at baseline, at 3 to 6 months, and annually during TRT. The Endocrine Society recommends withholding or dose-reducing if hematocrit exceeds 54% (Bhasin S, et al. J Clin Endocrinol Metab. 2018). Elevated hematocrit is one reason supraphysiologic testosterone doping increases thrombotic risk.

Prostate Monitoring

Men on TRT require PSA monitoring at 3 to 6 months after initiation and annually thereafter. A PSA rise of more than 1.4 ng/mL above baseline within the first 12 months of therapy warrants urological referral (Mulhall JP, et al. J Urology. 2018).

The Regulatory Field: MLB Rules vs. Medical Law

A player on MLB's 40-man roster needs a Therapeutic Use Exemption (TUE) to use testosterone for a documented medical condition. The TUE process requires objective laboratory evidence of deficiency, a physician attestation, and review by the MLB-MLBPA Health Policy Advisory Committee. Retired players are no longer subject to MLB drug testing and may legally obtain testosterone via prescription from a licensed physician, provided they meet medical criteria. This distinction matters. What Rodriguez did as an active player was prohibited regardless of dose. What any adult man does after retirement is governed by federal and state prescribing law, not a collective bargaining agreement.

Separating PED Doping from Legitimate TRT: A Clinical Framework

Clinicians and patients often ask how to distinguish illicit testosterone use from supervised therapy. Several parameters help.

Laboratory Markers

Supraphysiologic doping suppresses LH and FSH toward zero while raising testosterone far above 1,000 ng/dL. Therapeutic TRT targeting the mid-normal range (400 to 700 ng/dL) still produces LH suppression, which is why some clinicians co-administer human chorionic gonadotropin (hCG) to preserve testicular function and fertility. A serum LH near zero combined with a testosterone level above 1,200 ng/dL should prompt questions about dose accuracy or compliance with a prescribed protocol (Basaria S. Lancet. 2014).

Formulation Choices

Testosterone cypionate (injectable, 50 to 200 mg every 1 to 2 weeks) and testosterone enanthate are the most common US formulations. Topical gels (AndroGel 1%, 1.62%; Testim) and transdermal patches offer daily dosing. Pellet implants (Testopel) release testosterone over 3 to 6 months. The cream formulation implicated in the Biogenesis case is a compounded product not FDA-approved as a standalone product, though compounding pharmacies may prepare it under 503A or 503B regulations. Compounded testosterone products require the same physician oversight as brand-name formulations.

Monitoring Schedule

The Endocrine Society recommends checking serum testosterone 3 to 6 months after starting therapy, then annually. Targets are the mid-normal range for the assay being used. Bone mineral density, lipid panel, hematocrit, and PSA round out the surveillance program (Bhasin S, et al. J Clin Endocrinol Metab. 2018).

What Other Experts Have Said

The distinction between doping and therapy has been articulated by clinicians working at the intersection of sports medicine and endocrinology. Dr. Shalender Bhasin, director of the Research Program in Men's Health at Brigham and Women's Hospital and lead author of the Endocrine Society guideline, has stated in published commentary: "The doses used by athletes to enhance performance are substantially higher than those used therapeutically, and the intent, the monitoring, and the health consequences are entirely different." Bhasin S. Endocrine Society Clinical Practice Guideline. JCEM. 2018.

The FDA's drug safety communication on testosterone products notes that "the benefits and safety of using testosterone to treat 'age-related hypogonadism' have not been established," reinforcing that a confirmed diagnosis, not subjective aging complaints, is the required threshold for prescribing (FDA. Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging. 2015).